Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $2.70 to $2.80
• 50-Day Range: $2.67 to $6.20
• 52-Week Range: $2.65 to $18.30
• Volume: 27,934 shs
• Average Volume: 75,182 shs
• Market Capitalization: $1.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bone Biologics Stock Analysis - MarketRank™

Bone Biologics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bone Biologics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bone Biologics are expected to grow in the coming year, from ($5.00) to ($1.95) per share.

Price to Book Value per Share Ratio

Bone Biologics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.89% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently decreased by 91.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bone Biologics does not currently pay a dividend.

Dividend Growth

Bone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.89% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently decreased by 91.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for BBLG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Bone Biologics is held by insiders.

Percentage Held by Institutions

Only 34.30% of the stock of Bone Biologics is held by institutions.

BBLG Stock Analysis - Frequently Asked Questions

How have BBLG shares performed this year?

Bone Biologics' stock was trading at $5.6418 on January 1st, 2025. Since then, BBLG shares have decreased by 51.6% and is now trading at $2.73.

How were Bone Biologics' earnings last quarter?

Bone Biologics Corp. (NASDAQ:BBLG) announced its earnings results on Monday, May, 12th. The company reported ($1.92) earnings per share for the quarter, beating the consensus estimate of ($2.88) by $0.96.

When did Bone Biologics' stock split?

Bone Biologics shares reverse split on the morning of Tuesday, June 10th 2025.The 1-6 reverse split was announced on Friday, June 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Bone Biologics IPO?

Bone Biologics (BBLG) raised $8 million in an initial public offering on Wednesday, October 13th 2021. The company issued 1,510,455 shares at a price of $5.25 per share.

How do I buy shares of Bone Biologics?

Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Broadcom (AVGO), NVIDIA (NVDA), Annovis Bio (ANVS), CrowdStrike (CRWD), Dell Technologies (DELL), FedEx (FDX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBLG
• Previous Symbol: NASDAQ:BBLG
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.21%
• Return on Assets: -119.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.60
• Quick Ratio: 12.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.39 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 550,000
• Free Float: 512,000
• Market Cap: $1.50 million
• Optionable: Not Optionable
• Beta: 0.69